- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Chembio Diagnostics secured a $5.8 million order from Bio-Manguinhos/Fiocruz for test components and intermediate product of DPP HIV 1/2 Assay in Brazil.
Chembio Diagnostics (NASDAQ:CEMI) secured a $5.8 million order from Bio-Manguinhos/Fiocruz for test components and intermediate product of DPP HIV 1/2 Assay in Brazil.
As quoted in the press release:
Chembio further announced that it also has received GMP (Good Manufacturing Practices) certification for the Chembio New York manufacturing facility from Brazil’s health regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA), which certification was granted for Chembio in collaboration with Bio-Manguinhos/Fiocruz.
Bio-Manguinhos is a subsidiary of the Oswaldo Cruz Foundation (Fiocruz), which is responsible for the development and production of vaccines, diagnostics and biopharmaceuticals, primarily to meet the demands of Brazil’s national public health system.
John Sperzel, Chembio’s CEO, commented, “We commend the decision by Brazil’s Ministry of Health to purchase the high-quality DPP® HIV 1/2 Assay from Bio-Manguinhos, using both blood and oral fluid, for the country’s HIV testing programs. The use of rapid POC diagnostic tests, along with prevention and treatment, are essential elements of Brazil’s response to HIV incidence, and we are pleased to play an important role in the country’s effort to reduce HIV infection rates and identify patients who will benefit from antiretroviral treatment.”
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.